NCT04205409 · OUTCOME

Duration of Response

Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies · Source last updated 2026-06-26

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: months
Interval / dispersion: Full Range
Time frame: Up to 1 year and 7 months

What was measured

Will employ Kaplan-Meier and Cox proportional hazard model methodology.

Groups in this outcome

Treatment (Nivolumab)

Patients receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Nivolumab: Given IV

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Treatment (Nivolumab)	3

Reported measurements

Source class 1

Values in months · Interval/dispersion: Full Range
Group	Value	Spread	Lower	Upper	Comment
Treatment (Nivolumab)	18.3	Not reported	1.6	18.9	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
1.6
upper Limit
18.9
value
18.3

denoms

counts
group Id
OG000
value
3
units
Participants

description

Will employ Kaplan-Meier and Cox proportional hazard model methodology.

dispersion Type

Full Range

groups

description
Patients receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Nivolumab: Given IV
id
OG000
title
Treatment (Nivolumab)

param Type

MEDIAN

reporting Status

POSTED

time Frame

Up to 1 year and 7 months

title

Duration of Response

type

SECONDARY

unit Of Measure

months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice